Clinical Trials
11 trialsNCT06751524 2026-05-15
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
Agenus Inc.
Available
NCT07573215 2026-05-07
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
Revolution Medicines, Inc.
Available
NCT07399015 2026-02-18
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
Endevica Bio
No longer available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04087889 2025-09-29
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Hope Biosciences Research Foundation
No longer available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT04137822 2020-08-14
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Impatients N.V. trading as myTomorrows
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available